Browse by Audience
MEMBER

Update Your Profile
Member Spotlights
Refer a Member: IASP Champions
Join a Special Interest Group (SIG)
Find a Chapter
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Papers of the Week
Webinars and Podcasts
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Webinars & Podcasts
Curricula
Graduate Opportunities
Events

PATIENT & CAREGIVER

RELIEF News
Resources for Living with Pain
Global Alliance of Partners in Pain Advocacy (GAPPA)
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner

gy2022-1-3
I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Immunogenicity of erenumab: A pooled analysis of six placebo-controlled trials with long-term extensions.

< BACK TO ARCHIVE


Papers: 12 Mar 2022 - 18 Mar 2022


Human Studies, Pharmacology/Drug Development

PAIN TYPE:
Migraine/Headache


2022 Mar 10


Cephalalgia


http://www.ncbi.nlm.nih.gov/pubmed/35272533?dopt=Abstract

Immunogenicity of erenumab: A pooled analysis of six placebo-controlled trials with long-term extensions.

Authors

Immunogenicity of erenumab: A pooled analysis of six placebo-controlled trials with long-term extensions.
Zhou Y, Zhang F, Starcevic Manning M, Hu Z, Hsu C-P, Chen P-W, Peng C, Loop B, Mytych DT, Paiva da Silva Lima G
Cephalalgia. 2022 Mar 10:3331024221075621.
PMID: 35272533.

Abstract

Immunogenicity of erenumab, a human anti-calcitonin gene-related peptide receptor monoclonal antibody developed for migraine prevention, has been evaluated throughout clinical development.
Read This Paper